Latest news with #remotemonitoring
Yahoo
a day ago
- Business
- Yahoo
Biotricity Reinforces Growth Trajectory, Kicking Off Fiscal 2026 with Strong First Quarter Results Featuring Revenue Growth, Positive EBITDA and Improved Margins
REDWOOD CITY, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company'), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today announced its financial results for its first quarter of fiscal 2026, ended June 30, 2025. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "We're proud to deliver another quarter of strong performance and a shift to positive EBITDA, which demonstrates the scalability of our business model and strength of our team. Management believes that this a foundational milestone for Biotricity, exemplifying our ability to grow our business as we go from a loss-producing startup to a business that can operate profitably. Following a massive year of positive transformation for Biotricity, we continue to harness the power of workflow automation, AI technology, and other technological enhancements to further improve our operational expenses, margins, and revenues. This powerful combination has set the foundation to fuel ongoing growth. In doing so, we demonstrate our ability to scale with strategic focus and long-term sustainability. The expansion of our Cardiac AI Cloud platform, empowered by strategic partnerships with industry giants, showcases our commitment to revolutionizing medical diagnostics and consumer healthcare. Leveraging over 2 trillion beats of anonymized data, our AI-driven platform is set to enhance clinic profitability, paving the way for transformative advancements in diagnostic accuracy and patient outcomes. Importantly, we remain on track to pursue FDA clearance for our groundbreaking AI clinical model in the coming months. Strategic alliances forged during fiscal 2025 and 2026 have positioned us to capitalize on expansive market channels, providing access to approximately 90% of all hospitals in America and opening the door to managed care programs, which is a new vertical strategy for Biotricity. These developments mark a significant leap forward in our mission to deliver innovative, accessible, and high-quality cardiac care solutions." Q1-FY26 Financial Highlights Revenue increased 21% to $3.9 million, compared with $3.2 million in Q4 FY24 Gross margin was 80.5% for the three months ended June 30, 2025, as compared to 73.8% in the corresponding prior year quarter; this is the result of expansion in the recurring technology fee revenue base, efficiencies gained in using proprietary AI in operational automation, and improvement in monitoring and cloud cost structure. Net loss decreased to $0.75 million, or $0.03 per share, from a net loss of $6.9 million, or $0.49 per share, in Q1-FY25; this was an 80.6% improvement even after removing the effects of a $3 million one-time deemed dividend in the corresponding prior year period. Positive EBITDA of $333,337, first time in the Company's history; EBITDA increased by 118.7% compared to corresponding prior year quarter; this is the result of growth and operating efficiencies. Operating Highlights for Q1-FY26 and the Future Q1-FY26 recurring (TaaS) Technology Fees rose a robust 11.8% from the corresponding period of the prior year, to $3.4 million, which is also 7.9% increase from the immediately preceding three-month period. Company maintained its track record of strong customer retention, supported by the quality of customer and physician-friendly support services which emphasize the accuracy of our diagnostics and ease-of-use of our solution. Leveraging on its adept development of a range of state-of-the-art products to service a total addressable market of $35 billion. Working on achieving regulatory approval in internation markets, with a view to laying the foundation for distribution in those markets in the coming years, after successfully achieving approvals in Canada, Saudi Arabia and Argentina. Expansion of geographic footprint across 70% of the US, with penetration across thousands of physicians over hundreds of centers, including those acquired through relationships with strategic partners. Secured strategic alliances with three of the top GPOs representing 90% of all hospitals in the US. Full details of the Company's financial results will be filed with the SEC on Form 10-Q and available by visiting Financial Results and Business Update Conference Call Management will host a conference call on Thursday August 14, 2025 at 4:30 p.m. ET to discuss its financial results for fiscal first quarter of 2026 and provide a business update. Additional details are available under the Investor Relations section of the Company's website: Event: Biotricity First Quarter Fiscal 2026 Financial Results and Business Update CallDate: Thursday, August 14, 2025Time: 4:30pm ET (1:30pm PT) Toll Free: 1-877-269-7751 International: 1-201-389-0908 Webcast URL: Investors can begin accessing the webcast 15 minutes before the call, where an operator will register your name and organization. The call will be in listen-only mode. A replay of the call will be available approximately three hours after the live call via the Investors section of the Biotricity website at Toll Free Replay Number: 1-844-512-2921 International: 1-412-317-6671 Replay Access ID: 13755374Expiration: Thursday, August 28, 2025 at 11:59 PM ET About Biotricity Inc. Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The Company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit Non-GAAP Measures Non-GAAP financial information presented may be determined or calculated differently by other companies and may not be directly comparable to that of other companies. It is management's intent to provide non-GAAP financial information to enhance the understanding of Biotricity's GAAP financial information, and it should be considered by the reader in addition to, but not instead of, the financial statements prepared in accordance with GAAP. We believe that providing these non-GAAP measures in addition to the GAAP measures allows management, investors and other users of our financial information to more fully and accurately assess business performance. Earnings before interest, tax, depreciation and amortization ('EBITDA') is one such measure: 3 months endedJune 30,2025 3 months endedJune 30,2024 $ $ Net loss attributable to common stockholders (754,293 ) (6,948,292 ) Add: Provision for income taxes - - Interest expense 850,254 768,673 Accretion and amortization expenses 153,572 1,144,728 Depreciation 1,488 1,488 Preferred stock dividends 82,316 3,253,772 EBITDA 333,337 (1,779,631 ) Weighted average number of common shares outstanding 26,284,734 14,169,441 Profit (Loss) per Share, Basic and Diluted 0.013 (0.126 ) Important Cautions Regarding Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Contacts Investor RelationsBiotricity Investor RelationsInvestors@ SOURCE: Biotricity Inc.
National Post
07-08-2025
- Health
- National Post
Orpyx Launches Sensory Insole Program to Combat >$80B Annual Cost of Diabetic Foot Complications
Article content CALGARY, Alberta — Orpyx® Medical Technologies Inc., a leader in sensor-based remote monitoring, today announced the launch of its next-generation sensory insole program, a proactive, scalable solution to prevent the most costly and preventable consequences of diabetes. In the US alone, one in every three diabetes-related healthcare dollars goes toward managing foot-related complications, representing over $80 billion annually (Armstrong et al., Journal of Foot and Ankle Research, 2020). Article content Article content The Orpyx® Sensory Insoles are embedded with proprietary sensors that continuously track plantar pressure, foot temperature, step count, and wear time — physiological indicators that signal early deterioration in foot health. Designed for effortless patient use, the insoles function for up to six months without charging and sync with an intuitive mobile app and home hub that uploads data directly and securely to the Orpyx cloud. 'This new platform combines durable wearable technology and behavioral support to enable healthcare providers to intervene early before complications escalate,' said Dr. Breanne Everett, CEO and founder of Orpyx. 'Our goal is to help people stay healthy, avoid hospitalizations, and maintain control over their health. This launch is a key milestone as we scale across government and commercial value-based care markets, supporting high-risk individuals while delivering meaningful value for healthcare systems and payers who are under increasing pressure to improve outcomes while managing costs more effectively.' Article content Each program participant is paired with a dedicated Orpyx nurse who delivers personalized coaching, adherence support, and wellness checks, bridging the gap between medical appointments to help ensure continuity of care. This model supports both better outcomes and operational scalability for chronic disease management programs. Article content The Orpyx technology is clinically validated and economically proven in multiple peer-reviewed publications. In a randomized controlled trial, individuals who wore an earlier-generation Orpyx insoles for 4.5+ hours daily experienced an 86% reduction in foot re-ulceration (Abbott et al., Lancet Digital Health, 2019). A separate cost-effectiveness study reported an 84% reduction in ulcer occurrence within three months, along with a 70% decrease in total projected costs (Najafi et al., Wound Care Management, 2018). Article content 'This product launch represents a significant advancement in orthotic technology. Clinicians can now medically monitor or intervene with patients living with chronic foot conditions that put them at risk for serious complications', said Dr. Daniel Ferreras, DPM, FAPWCA, AAWC. 'By combining clinically validated technology with personalized support, we're providing patients the tools they need to stay healthier, avoid hospitalization, and maintain their independence.' Article content Foot complications are a leading cause of diabetes-related hospitalization, amputation, and long-term disability, which are largely preventable with early detection and intervention. The Orpyx Sensory Insole program is built to support value-based care models for health systems, ACOs, and payers focused on managing this high-risk, high-cost population living with diabetes. Article content About Orpyx Medical Technologies Inc. Article content Orpyx® is a health technology company transforming the prevention of diabetic foot complications through its patented sensor-enabled smart insole system and integrated remote care program. Built to detect early warning signs and prompt timely intervention, the Orpyx solution helps improve adherence, reduce total costs, and preserve mobility and quality of life. The company partners with VA Medical Centers, health systems, and payers across North America to deliver clinically validated outcomes and cost savings at scale. Article content Article content Article content Contacts Article content Media Inquiries: Article content Article content Karen Smith Article content Article content
Associated Press
21-07-2025
- Business
- Associated Press
Nestmedic Selects Curavit Clinical Research as U.S. CRO Partner for Pioneering Prenatal Monitoring Trial
BOSTON and WARSAW, Poland, July 21, 2025 /PRNewswire/ -- Curavit Clinical Research, 'The Innovation CRO', is proud to announce its selection by Nestmedic S.A. to lead the U.S. clinical trial of PregnaOne, an innovative remote prenatal monitoring solution. This milestone partnership was recently shared on LinkedIn by Nestmedic CEO Jacek Gnich and Curavit leadership. The upcoming Non-Significant Risk (NSR) study will enroll 50 expectant mothers in the U.S. to evaluate the safety and effectiveness of PregnaOne during home use. The study is designed to generate foundational evidence to support future regulatory approval in the U.S. Curavit will manage all aspects of the trial, including IRB submissions, site selection, contract and monitoring, data management, clinical data capture software selection, data analytics, and preparation of the Clinical Study Report (CSR). 'We are honored to support Nestmedic in bringing PregnaOne to market,' said Joel Morse, CEO and Co-founder of Curavit Clinical Research. 'Their mission to improve prenatal care through remote monitoring perfectly aligns with Curavit's vision to partner with innovative medical device companies that are working to expand access to healthcare.' Trial Highlights: 'We are building technology with empathy at its core,' said Jacek Gnich, CEO of Nestmedic. 'Curavit's innovation forward approach, medical device expertise, and deep clinical trial experience make them the ideal partner to run this pivotal study in the U.S.' About Curavit Clinical Research Curavit Clinical Research, The Innovation-CRO, designs and executes modern clinical trials for medical devices, digital therapeutics, and novel pharmaceuticals. Headquartered in Boston, Curavit operates nationwide with additional offices in New York, Salt Lake City, and San Diego. Learn more at About Nestmedic S.A. Nestmedic is a Polish medtech company redefining prenatal care with PregnaOne, an AI-enabled remote monitoring solution that empowers patients and providers with real-time, continuous insight into fetal and maternal well-being. View original content to download multimedia: SOURCE Curavit Clinical Research
Globe and Mail
19-06-2025
- Business
- Globe and Mail
Cardiac Event Monitor Market Set to Reach USD 7.39 Bn by 2032 with 5.9% CAGR
The market trend for the cardiac event monitor market is driven by several factors, including the increasing prevalence of cardiovascular diseases, the growing geriatric population, and the rising adoption of remote monitoring technologies. Additionally, the development of advanced and user-friendly cardiac event monitors, coupled with the increasing demand for home-based healthcare solutions, is expected to further fuel market growth during the forecast period. Cardiac Event Monitor Market Insights The Cardiac Event Monitor market is witnessing robust business growth driven by rising cardiovascular disease prevalence and digital health integration. Advanced monitoring solutions are reshaping industry size and fueling market analysis for stakeholders seeking deeper market insights. This outlook aligns with the market forecast through 2032 and reflects evolving market dynamics. The Global Cardiac Event Monitor market size is estimated to be valued at USD 4.95 Bn in 2025 and is expected to reach USD 7.39 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 5.9% from 2025 to 2032. This market report highlights the expansion of external and implantable monitoring devices, underpinned by rising arrhythmia detection demand. Recent market research indicates that 2024 shipments surpassed 1.3 million units globally, underpinning revenue growth across North America and Europe. The Cardiac Event Monitor market report offers detailed market segments, market drivers, and market restraints for strategic planning. Market Key Takeaways Regions: • North America: Strong reimbursement frameworks driving early adoption of advanced monitors. • Latin America: Growing investments in telehealth infrastructure boosting device penetration. • Europe: Government initiatives for cardiac care expansion fueling demand. • Asia Pacific: Rapid urbanization and rising healthcare expenditure accelerating uptake. • Middle East: Infrastructure upgrades in GCC countries supporting remote monitoring. • Africa: Pilot programs and NGO funding enhancing diagnostic access. Segments: • Device Type – External Loop Recorders, Implantable Loop Recorders (e.g., long-term arrhythmia use cases). • End User – Hospitals & Clinics, Ambulatory Care Centers (use case: continuous outpatient monitoring). • Application – Arrhythmia Detection, Syncope Management (example: post-stroke cardiac surveillance). Growth Factors • Cardiovascular Disease Surge: In 2024, global arrhythmia diagnoses rose by 7.2%, driving market growth. • Telehealth Reimbursement Expansion: U.S. reimbursement policies now cover up to 85% of remote monitoring costs, up from 60% in 2023. • Aging Population: By 2025, adults over 65 will constitute 18% of Europe's population, boosting market opportunities for long-term monitoring. • Technological Innovation: Integration of AI-driven analytics enhanced diagnostic accuracy by 15% in pilot trials during early 2024. • Market drivers include rising patient self-care and regulatory support, offsetting market restraints like high device costs. Book the Latest Edition of this Market Study Get Up to 25 % Discount: Market Trends • Telemonitoring Platforms: Adoption of cloud-based cardiac event platforms grew 22% in 2024, reshaping Cardiac Event Monitor market trends. • Wearable Integration: Hybrid monitors pairing wearable patches with smartphone apps increased user compliance by 12% year-on-year. • AI-Enabled Analytics: In 2025, AI algorithms reduced false-positive alerts by 25% in clinical deployments. • Miniaturization: Implantable monitors shrank by 30% in size between 2023 and 2025, expanding pediatric applications. • Subscription Models: Recurring-revenue models contributed 18% of total market revenue in 2024, illustrating evolving market scope. Actionable Insights • Production Capacity: Global manufacturing capacity reached 1.6 million units in 2024, up 9% from 2023. • Pricing Trends: Average selling price per device declined by 3% in 2024, enhancing affordability. • Exports & Imports: Exports expanded by 11% in 2024, led by Europe; imports rose 7% in Asia Pacific, signaling market opportunities. • Use Cases: Remote patient management deployments increased 14% in 2025, with hospitals accounting for 60% of demand. • Micro-Indicators: Drill-down data show outpatient clinics growing device orders by 8% per quarter in 2024. • Nano-Indicators: Country-level permit approvals jumped by 20% in emerging markets, reflecting favorable market dynamics. Key Players • Medtronic • Boston Scientific Corporation • Abbott • GE Healthcare • Philips Healthcare • Biotronik • Hill-Rom Holdings (Baxter) • iRhythm Technologies • Preventice Solutions • Medicomp • ACS Diagnostics • Spacelabs Healthcare • Nihon Kohden Corporation Get Customization on this Report: Competitive Strategies: • Medtronic expanded its Asia Pacific distribution network in 2024, boosting Cardiac Event Monitor market share by 4.5%. • Boston Scientific implemented value-based pricing in Europe, leading to a 10% uplift in Cardiac Event Monitor market revenue during H1 2025. • Philips Healthcare's strategic partnership with remote care platforms reduced device latency by 20%, enhancing customer retention and differentiating its offerings. Frequently Asked Questions 1. Who are the dominant players in the Cardiac Event Monitor market? Major market players include Medtronic, Boston Scientific, Abbott, GE Healthcare and Philips Healthcare, collectively driving product innovation and global reach. 2. What will be the size of the Cardiac Event Monitor market in the coming years? The market is projected to grow from USD 4.95 Bn in 2025 to USD 7.39 Bn by 2032, at a CAGR of 5.9%, according to the latest market forecast. 3. Which end-user industry has the largest growth opportunity? Hospitals and ambulatory care centers represent the largest growth opportunity, driven by continuous outpatient monitoring and integrated telehealth services. 4. How will market development trends evolve over the next five years? Key trends include AI-driven analytics, wearable integration, subscription models, and miniaturization, all reshaping market dynamics and creating new business growth avenues. 5. What is the nature of the competitive landscape and challenges in the Cardiac Event Monitor market? The landscape is consolidated among a few large companies focusing on innovation. Challenges include high device costs, reimbursement variability and stringent regulatory approvals. 6. What go-to-market strategies are commonly adopted in the Cardiac Event Monitor market? Strategies encompass regional partnerships, value-based pricing, digital platform integration, and direct-to-consumer telemonitoring services to enhance market penetration and customer engagement. About Coherent Market Insights Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.
Malay Mail
21-05-2025
- Business
- Malay Mail
81 Electrical Launches Control Panel Automation Services
81 Electrcial Unveils Control Panel Automation Services in Singapore Remote monitoring and control Real-time alerts via SMS and email Integration with existing ACMV, pump, and building management systems Energy-efficient design to lower operating costs Smart home & building automation Advanced electrical control panel solutions Swimming pool automation Remote monitoring & system control Industrial automation (PLC, HMI, SCADA) Pump & motor repair and servicing Optimising energy consumption Enabling predictive maintenance Reducing the risk of equipment failure SINGAPORE - Media OutReach Newswire - 21 May 2025 - 81 Electrical, an electrical service provider in Singapore, is proud to announce the launch of its latest offering: control panel automation. This new service is designed to bring advanced automation, remote monitoring, and energy-efficient solutions to industries, such as ACMV, water treatment, building management, and industries continue to evolve, the demand for smart, automated systems is on the rise. Recognising the inefficiencies of traditional manual control panels, 81 Electrical has developed an automation solution that incorporates PLC programming, HMI integration, and cloud-based remote monitoring. These innovations allow for increased operational efficiency, reduced downtime, and significant cost savings."Outdated control systems are holding businesses back. Our new automation service provides a smarter, more sustainable alternative that empowers clients with real-time control and insights," said Steven Koh, Director of 81 a solid foundation in electrical control systems and mechanical & electrical (M&E) services, 81 Electrical brings years of expertise to the control panel field. They specialise in automation, troubleshooting and repair services. In line with the company's mission, this new venture is unveiled to enhance performance, reduce operational costs, and modernise Singapore's electrical Sets It ApartThe launch also marks the beginning of a broader expansion. Upcoming services include:Control panel automation is not only about improving convenience; it also contributes to sustainability. 81 Electrical aims to help clients lower their carbon footprint and extend the lifespan of their systems by:While no formal partnerships have been announced, 81 Electrical is in active discussions with several technology providers to further enhance the service. "We're committed to staying ahead of the curve by continuously improving our offerings. Our goal is to provide smart, scalable solutions that meet our clients' evolving needs," as revealed by Steven Koh, Director of 81 Electrical. Additional system upgrades and customisations will be available upon #81Electrical #controlpanelautomationservices #electricalservicesinsingapore #electriciansingapore The issuer is solely responsible for the content of this announcement. About 81 Electrical 81 Electrical is an electrical service provider with over a decade of experience supporting both residential and commercial clients. The company offers a broad range of electrical works in Singapore, including electrical control panel troubleshooting and repair services.
